PATENT CLAIM ANALYSIS

Application Number: 16182146
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-02
Patent Classification: ["435", "320100"]

Abstract:
Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.

Claim (Index 1):
A method of making an engineered population of primary cells comprising: introducing a deoxyribonucleic acid encoding for at least a portion of an exogenous functional T cell receptor sequence or at least a portion of an exogenous functional chimeric antigen receptor sequence into a genomic disruption in a cytokine inducible SH2-containing protein (CISH) gene in a genome of at least one cell in a population of cells, wherein said genomic disruption is performed by an endonuclease and partially reduces or completely suppresses expression of said CISH gene.

Metadata:
- Claim Count in Document: 20.0
- Percentile: 98.0
- Lexical Diversity: 1.4
- Patent Class: 435.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15224151', '15250514', '15818649', '15606995', '15864947']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6750366895091702
- 35 USC 102 Novelty (BERT): 0.6362560013687638
- Combined Prediction Score: 0.6711586206951295
- Mean Citation Score: 450.252034
- Max Citation Score: 687.09875
- Similarity Product: 565.2866421705485

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test